Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Non-Current Assets data on file, last reported at $639.0 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 4.28% year-over-year to $639.0 million in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 12.54% decrease from a year earlier, with the FY2025 full-year figure at $581.0 million, down 15.31% from the prior year.
• Non-Current Assets for Q1 2026 stood at $639.0 million, up from $581.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for RARE reached as high as $758.8 million in Q4 2023 and fell as low as $547.2 million in Q3 2025.
• Historically, Non-Current Assets has averaged $645.1 million across 5 years, with a median of $639.0 million in 2026.
• Across the five-year window, Non-Current Assets grew 28.41% in 2022 and decreased 25.92% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $661.5 million in 2022, then increased by 14.71% to $758.8 million in 2023, then dropped by 9.6% to $686.0 million in 2024, then declined by 15.31% to $581.0 million in 2025, then gained by 9.98% to $639.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $639.0 million in Q1 2026, $581.0 million in Q4 2025, and $547.2 million in Q3 2025.